Target
BCR::ABL1
4 abstracts
Abstract
Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.Org: Versiti Blood Research Institute, Division of Hematology and Oncology, Medical College of Wisconsin, Imperial College London, Royal North Shore Hospital, Singapore General Hospital, Duke-NUS Medical School,
Abstract
Disparities in frontline treatment and overall survival in the era of targeted tyrosine kinase inhibitor therapy for chronic myeloid leukemia: 2004-2021.Org: University of Utah, Huntsman Cancer Institute,
Abstract
In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL.Org: Hospital Universitario Dr. José Eleuterio González, University of Milano-Bicocca, ICO – Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute,
Abstract
Comparing GIST outcomes between geriatric and non-geriatric patients: A population-based analysis.Org: Worcester Academy, Northwell Health, New Hyde Park, NY, Northwell Heath,